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Pregnancy is a physiological state that alters the body’s response to infections. 
COVID-19 has been found to cause severe disease in pregnancy with morbidity 
and mortality that is higher than in non-pregnant adults. There is risk of transmis-
sion of SARS-CoV2 infection to fetus during ante-natal period, intra-partum and 
post-delivery from an infected mother. It is necessary to provide an un-interrupted 
ante-natal care and delivery services to pregnant women during the pandemic. 
Tele-consultation is important modality to reduce the physical exposure of pregnant 
women to the hospital environment and should be utilised. Screening, isolation, 
testing and treatment for SARS-CoV2 infection in pregnant women should follow 
the local guidelines and remain essentially the same as in non-pregnant adults. 
Admission, if required, should be in a facility that can provide obstetric maternal 
and fetal monitoring in addition to care for COVID-19 illness. Use of nitrous oxide 
and inhalational oxygen for fetal indication should be avoided during labor. Second 
stage of labor is considered an aerosol generating procedure and should be managed 
with adequate precautions. Mode of delivery should be as per obstetric indications. 
Regional anaesthesia should be preferred during caesarean. COVID-19 is not a 
contra-indication to breast feeding. For antenatal women, COVID-19 vaccination 
can be considered after shared decision making.
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1. Introduction
Pregnancy is a physiological state that alters the body’s immune system and 
response to viral infections. Pregnant women have been found to have higher risk 
of complications during the previous corona virus outbreaks, namely Severe Acute 
Respiratory Syndrome (SARS) in 2002–2004 and Middle East Respiratory Syndrome 
(MERS) in 2012. The risk of maternal morbidity and mortality was high with these 
infections. With Covid-19, though initially there were different opinions but currently 
there is sufficient evidence to suggest that pregnant women are at increased risk for 
complications of COVID19. Additionally, there is evidence to support risk of transmis-
sion of infection to fetus intra- or postpartum and concerns about obstetrical outcome.
2. Physiological changes in pregnancy and SARS-CoV2 infection
Pregnancy induces changes in all organ systems of body, notable one being a 
state of altered immunity and body’s response to various infections. This results in 
increased severity of illnesses during pregnancy as evidenced in previous respira-
tory disease outbreaks.
Changes in pregnancy that alter the response to illness are:
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2.1 Immune system
a. Shift in population of CD4+ T Cells population towards Th2 phenotype 
 promoting humoral immunity in place of cellular immunity [1].
b. Decrease in the population of natural killer cells, possibly altering viral 
 clearance [2].
c. Phagocytic dendritic cells are decreased and so, interferon response to viruses 
is altered [3]
d. Hormonal changes in the form of increased progesterone, oestrogen and 
androgens alter the body’s immune system because of immunomodulatory 
properties [4]. Whether these hormones predispose to severe disease or have 
protective effect is yet to be known.
2.2 Respiratory system
a. Elevation of diaphragm due to gravid uterus leading to reduction in lung 
 volume and total lung capacity.
b. Increase in tidal volume (30–40%)
c. Decrease in functional residual capacity, residual volume and end 
 expiratory volumes
d. Decreased clearance of secretions
These changes make pregnant women more susceptible to severe disease [5].
2.3 Coagulation pathway
Pregnancy is a hypercoagulable state with:
a. increase in thrombin and other coagulation factors
b. increased fibrinolytic factors such as plasmin
Covid 19 is associated with high rate of thromboembolic complications which is 
compounded by changes of pregnancy.
2.4 Vascular system
Pregnancy increases maternal blood volume, heart rate and cardiac output while 
systemic resistance decreases. There is an increase in intravascular inflammation 
[6]. These vascular changes have the potential to impact endothelial function which 
is a major factor in development of Acute Respiratory Distress Syndrome (ARDS) 
with Covid19.
Preeclampsia is an important complication of pregnancy associated with 
endothelial cell dysfunction and higher rates of preeclampsia have been noted in 




3. Physiology of placenta and placental transmission of COVID-19
Placenta acts as a barrier for transmission of pathogens by various mechanisms. 
Placental decidua contains large number of NK cells, macrophages and T cells. 
Decidual macrophages perform antimicrobial functions while CD8+ T cells protect 
the fetus from viral infections [8]. Additional protection is provided by syncytio-
trophoblast and cytotrophoblast mediated by toll-like receptors. Placenta also has 
antimicrobial peptides which prevent fetal transmission of various pathogens [9].
The first prerequisite for transmission of any virus through placenta is viremia, 
which, in case of SARS-CoV2, may be present for a relatively short duration. 
Although earlier studies documented viremia in only 1–15% of patients infected 
with SARS-CoV2 virus, recent study using WHO RT-qPCR protocol demonstrated 
viremia in up to 80% patients, although mostly with low levels of viral load [10].
The second element necessary for fetal transmission is placental tropism or 
the ability of the virus to infect placental cells. In lungs, SARS-CoV2 uses ACE-2 
receptor to enter cells and a serine protease named TMPRSS2 to cleave the spike 
glycoprotein, facilitating fusion. Although ACE-2 and TMPRSS2 have not been 
shown to be co-expressed in placental cells, they have been demonstrated in tropho-
blast, blastocyst and hypoblast. It has been suggested that SARS-CoV2 could enter 
placenta using other proteases like DPP4, CD147 or trypsin [11].
Another route for this virus to enter the placenta could be through infected 
blood cells like lymphocytes and macrophages but this has not been proven yet for 
SARS-CoV2. Transcytosis of free virus particles can infect the fetus, as in case of 
HIV but this method is thought be less important with maternal SARS-CoV2 infec-
tions because of low viremia.
Infection may also cross over to fetus through cervico-vaginal secretions which 
would raise concerns for the mode of delivery of the fetus. The evidence we have till 
now does not favour this mode of transmission as one study on ten infected women 
did not find viral RNA in vaginal secretions in any patient [12].
There is convincing evidence that placental transmission of the virus causing 
COVID-19 is possible, though rarely. Presence of SARS-CoV2 viral RNA in placenta 
and SARS-CoV2 virions in syncytiotrophoblast has been reported in multiple cases. 
IgM antibodies directed against SARS-CoV2 virus have been documented in neo-
nates born to mothers with SARS-CoV2 infection, making a strong case for in-utero 
transmission of this virus [13].
Placental histology in parturient women who contracted SARS-CoV2 infection 
during the ante-natal period shows vascular malperfusion, chronic villitis, placental 
infarcts and fibrin deposition [14].
It has been estimated that maternal to fetal transmission occurs in 3.2% of 
pregnant women infected with SARS-CoV2 virus. Viral positivity rate for placental 
and cord samples and fetal serology fall in the same range, supporting the transmis-
sion rate of 3.2% [13].
4. Effects of SARS-CoV 2 infection on pregnant women
Pregnancy is an immuno-deficient state and high morbidity has been reported 
during previous corona virus outbreaks, both MERS and SARS. Earlier studies done 
in China showed key outcomes in pregnant women infected with SARS-CoV2 virus 
to be similar to those in non-pregnant adults [15, 16]. These studies were limited by 
small sample sizes and a retrospective design. A national analysis of all Covid related 
ICU admissions in Sweden was one of the first studies to report increased morbidity 
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during pregnancy [17]. Studies later done in France and the USA supported these 
findings. The largest study addressing this topic was the review of all laboratory con-
firmed cases of Covid19 from January to June 2020 in the USA. They found increased 
risk of hospitalisation, ICU admission and mechanical ventilation but not mortality 
[18]. This data was recently updated through October 2020 to report increased risk of 
hospitalisation, ICU admission, mechanical ventilation, extracorporeal membranous 
oxygenation (ECMO) and death [19]. Though risk appears to be increased when 
compared with non-pregnant adults, absolute risk remains low.
Clinical course of COVID-19 is believed to be mild in majority (86%) of preg-
nant females, severe in 9% and critical in 5% [20]. This is similar to incidences 
reported in non-pregnant Covid19 patients.
In data reported from the UK, most women with more severe illness were in third 
trimester of pregnancy or postpartum [21]. Risk factors associated with hospital 
admission in pregnant women include Black, Asian or minority ethnicity, pre-existing 
co-morbidity (e.g. diabetes, hypertension, asthma), obesity/overweight and maternal 
age more than 35 years. It has been postulated that this risk is due to genetic differ-
ences, socio-economic disparity or difference in response to infection. Vitamin D 
deficiency has been associated with respiratory infections and ARDS, a common com-
plication of Covid19. South Asian population has been documented to be deficient in 
Vitamin D and this could be a factor in increased morbidity in this population [21].
COVID-19 increases the risk of thromboembolic complications and pregnancy 
is itself associated with increased risk of thrombo-embolism. Royal College of 
Obstetricians and Gynaecologists (RCOG) has emphasised the risk of throm-
boembolism in COVID-19 with pregnancy and recommends appropriate use of 
thromboprophylaxis.
5. Risks to the fetus
Many studies have shown increased chances of preterm delivery in SARS-CoV2 
infected women. Most of these preterm births have been seen to be iatrogenic. Most 
of the preterm babies have been delivered by caesarean section due to intrauterine 
foetal distress. Symptomatic women have been found to have increased risk of 
preterm delivery compared to asymptomatic SARS-CoV2 infected women. Some 
studies have shown a decrease in mean gestational age at the time of delivery in 
women who were diagnosed with COVID-19 within 14 days before delivery. One 
study also reported increased chances of stillbirth in foetuses born to SARS-CoV2 
positive mothers [22].
Till date no association has been found with first trimester losses or teratogenic-
ity and COVID-19 infection is not an indication for medical termination of preg-
nancy. Though this is ever changing situation and we may get more information in 
future as the evidence is pooled in. Amniocentesis to diagnose fetal infection is also 
not recommended at present [23].
6. Diagnostic testing for SARS-CoV2 infection in pregnancy
The criteria for testing pregnant women for SARS-CoV 2 infection remain the 
same as for general population. Local testing guidelines as per the local, state and 
regional governments should be followed. Basically, it includes testing symptomatic 




Nasopharyngeal swab is the recommended sample for testing, oropharyngeal 
swab is also acceptable. Lower respiratory samples are recommended in intubated 
patients and in those with severe illness and negative nasopharyngeal swabs.
RT-PCR is the most commonly used test in pregnancy. Nucleic Acid 
Amplification Tests (NAAT) can be used as per availability and regional guidelines.
Rapid antigen tests and serological tests can all be used in pregnancy as per 
regional protocols and there are no specific considerations for diagnostic testing in 
pregnancy [24].
7. Ante-natal care during COVID-19 pandemic
Providing adequate antenatal care during the COVID-19 pandemic is a prior-
ity and a minimum number of antenatal visits should be ensured. Federation 
International of Gynaecology and Obstetrics (FIGO) suggests a minimum of six 
in-person antenatal visits i.e. at 12 weeks, 20 weeks, 28 weeks, 32 weeks, 36 weeks 
and at 37–41 weeks. Telemedicine can be used for any additional advice and facili-
ties should be made available for tele-consultation.
Appointments should be taken before consultation and screening for any 
symptoms for COVID-19 should either be done telephonically or before entering 
the antenatal area [25]. Screening should include symptoms suggestive of COVID-
19 illness, any history of recent travel, history of exposure to infected person and 
any history of immune-suppression [25].
FIGO recommends that any pregnant women testing positive on screening 
should have a minimum waiting period, should be tested for severity of symp-
toms, and evaluated as per local guidelines [25]. Screen-positive women should be 
isolated and not allowed near other pregnant women.
Screen-positive woman who contacts telephonically should be advised to defer 
the visit for 14 days unless there is an urgent need.
During antenatal visits, pregnant woman should be counselled about the general 
measures to prevent spread of infection like social distancing, use of face masks and 
respiratory hygiene. They should be educated about the symptoms of SARS-CoV2 
infection and that even if they become infected, they are likely to have mild disease 
in most cases. They should be told that if they develop severe symptoms or recovery 
is delayed, they should seek care [25].
Pregnant women should be allowed only one accompanying person and he/she 
should also be screened at entrance to hospital.
They should also be counselled about the possible modifications in her antenatal 
plan in view of the ongoing pandemic. She should be told about dedicated COVID 
facilities in her neighbourhood and facilities where SARS-Cov2 positive women can 
deliver.
She should be advised to keep taking her routine health supplements e.g. folic 
acid during pregnancy.
There should a mechanism in place to track antenatal women who miss sched-
uled visits and they should be contacted telephonically.
Clinicians should be aware of the increased risk of psychological problems and 
domestic abuse during the pandemic and appropriate steps should be taken to 
address these issues including looking for signs, counselling and referral if needed. 
Particular concern has been raised about the increased need of psychological coun-
selling and support services to the antenatal women during this time of pandemic 
when face to face consultation is not possible [25].
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8. Antenatal care for women with suspected/confirmed covid-19
Care of symptomatic pregnant women suffering from Covid-19 should be a 
multidisciplinary team approach.
American College of Obstetricians & Gynaecologists (ACOG) has developed 
an algorithm for management of outpatient pregnant women with suspected or 
confirmed COVID-19. If a woman has no symptoms to suggest infection with 
SARS-CoV2, she should receive routine prenatal care. If she has symptoms, severity 
of symptoms should be assessed. Assessment of severity of illness should include 
any shortness of breath, coughing up blood, dizziness, chest pain, not being able to 
keep down fluids and any history of confusion. If any of these are present, pregnant 
woman is at elevated risk and should be asked to seek care in an emergency depart-
ment in a centre that has facilities for antenatal and obstetric care. If the woman has 
symptoms but those are not severe, she should be screened for any co-morbidities 
and any obstetric complications. If any co-morbidities or obstetric complications 
are present, she is categorised as having moderate risk and should be evaluated in 
ambulatory setting as soon as possible and should be investigated for severity of ill-
ness. CT Scan with abdominal shielding should be done if clinically indicated. If the 
woman does not have any high risk factors, she should be sent for symptomatic care 
at home, including hydration and rest and evaluated repeatedly for development of 
any of the above symptoms [26].
Indian Council of Medical Research (ICMR) recommends that symptomatic 
women with fever >38°C and respiratory symptoms should be hospitalised in a 
tertiary care centre with facilities for maternal and fetal monitoring. Seriousness 
of maternal situation is assessed by quick SOFA score, parameters of severity being 
systolic blood pressure < 100 mmHg, respiratory rate > 22, and Glasgow conscious-
ness scale <15. Any pregnant woman with more than one of these factors should be 
admitted in Intensive Care Unit (ICU) [27].
FIGO recommends anomaly scan at 18–23 weeks in women with confirmed 
SARS-CoV2 infection and monthly scan after that for fetal growth. ICMR (Indian 
Council for Medical Research) recommends a growth scan 14 days after recovery 
from acute illness [25].
9. Management during labor
9.1 Preparation before admission
Admission for labor and delivery represents a unique scenario in that admis-
sion, though planned, cannot be delayed. The basic principles remain the same as 
those for outpatient visits, i.e., to avoid unnecessary hospital visits, maintain social 
distancing and other measures to prevent spread of SARS-CoV2. Women should 
be advised to quarantine themselves or work from home at least 14 days before 
planned admission for delivery or caesarean. This should start in most women by 
37 weeks of gestation. Woman and her birthing partner should be screened for 
symptoms of COVID-19 telephonically one day before admission [28].
9.2 Screening on arrival
All women arriving for admission for delivery should be screened verbally 
for fever, cough and respiratory symptoms. Birthing partner should be similarly 




provider. Some women would already be diagnosed with SARS-CoV2 infection and 
they should directly be delegated to area dedicated for infected patients.
Case can be made for testing all women at the time of admission to labor and 
delivery unit because of high number of asymptomatic infections [20]. Local 
guidelines could also mandate testing at the time of admission.
After screening at the time of admission, women will be categorised into one of 
the three categories: infected, suspect and non-infected. Under ideal circumstances, 
all health care facilities caring for pregnant women should have well demarcated 
zones with separate passageways for all of these categories. These zones should 
include separate wards, intensive care areas and operation theatres. If not pos-
sible, all care should be taken to avoid infected and non-infected people coming in 
proximity of each other.
9.3 General precautions during admission
All women and their birthing partners should wear triple layer surgical masks 
throughout admission. All healthcare providers should wear triple layer surgical 
mask for each patient contact. Hands should be sanitised with alcohol based hand-
rub after every patient contact. Droplet precautions should be used when caring for 
women with respiratory symptoms. This requires the use of gloves, gown, surgical 
mask and face shield. Gown, gloves, face shield and N95 mask should be used for 
any woman with suspected COVID and during any aerosol generating procedure 
including second stage of labour [28]. Disinfection of rooms should be done 
between patients.
Women should be allowed to have one birthing partner who should stay 
throughout admission. Other support persons should be given option to provide 
support through video. Visitors should not be allowed in person, although visitation 
may be considered in end of life situations.
Shifting of woman from one area to other should be avoided and all efforts 
should be made to provide services at women’s bedside.
All preoperative investigations needed for caesarean should also be done on the 
day of admission to decrease the number of pre-admission hospital visits.
9.4 Intrapartum care
Management of first stage of labour remains essentially the same as in a woman 
not infected with Covid-19. Women with mild disease require management of fluid-
electrolyte balance during labor, in addition to symptomatic management and close 
monitoring of maternal well-being. Woman should be encouraged to take oral fluids 
to maintain hydration. Intravenous fluids should be used with caution because of 
association of Covid-19 with Acute Respiratory Distress Syndrome (ARDS) [25]. 
Early use of oxytocin for slow and dysfunctional labour is recommended to avoid 
the stress and complications of a prolonged labor. Use of Nitrous Oxide during 
labour should be avoided because of insufficient data about cleaning, filtering and 
potential aerosolization of nitrous oxide systems [28].
Oxygen is used intrapartum for fetal benefit, to increase fetal oxygenation. A 
recent meta-analysis has shown that it does not provide fetal benefit and may even 
be harmful [29, 30]. ACOG recommends against the use of oxygen therapy for fetal 
resuscitation during labour [28].
Second stage of labour is considered an aerosol generating procedure and should 
be managed with appropriate precautions. Obstetric management remains the same 
as before the pandemic.
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Blood resources have become scarce during the pandemic because of inability 
to conduct donation drives. Maintaining pre-delivery haemoglobin is the most 
efficient way to decrease the use of blood during labour and delivery admissions. 
Utmost importance should be given to aggressively treat anaemia detected during 
pregnancy. Blood transfusion should only be used when absolutely necessary and in 
minimum quantity.
Misoprostol and tranexamic acid should be used prophylactically in third stage 
of labor to decrease blood loss after delivery.
10. Management of pregnant woman with COVID-19
A pregnant woman with SARS-CoV2 infection should be counselled about the 
risk of serious infection and the methods to protect family members from infection. 
Next step is to assess systemic status of woman for severity of infection and need of 
hospitalisation.
Management of infection should be same as management of non-pregnant 
patients with COVID-19. If the patient needs hospitalisation, she should be 
admitted in a facility where maternal as well as fetal monitoring can be done 
[31]. The facility should be able to provide fetal and uterine contraction moni-
toring, individualised delivery planning and team based approach including 
obstetrician, paediatrician, anaesthetist and respiratory medicine specialist. 
The basic principles and medications remain the same as in non-pregnant 
patients. Potentially effective treatment for COVID-19 should not be withheld 
from pregnant women due to theoretical concerns regarding safety. Decisions 
regarding treatment options should be made keeping in mind safety of the 
 medication, the severity of maternal disease and in shared decision-making with 
the patient [31].
A very important limitation is exclusion of pregnant women from most clinical 
trials involving new treatment modalities and the safety data remains scarce.
In most cases, timing of delivery should not be altered by maternal COVID-19 
infection [32]. Patients who get infected in early pregnancy and subsequently 
recover do not require any change in the timing of delivery. For patients who 
contract SARS-CoV2 infection in the third trimester of pregnancy, attempt should 
be made to postpone delivery till negative SARS-CoV2 report or lifting of quar-
antine status to decrease the risk of perinatal transmission. Maternal COVID-19 
infection is not an indication for caesarean section, which should be done for 
obstetric indication or on maternal request [32]. Because the risk of transmission 
from umbilical cord blood is low, delayed cord clamping should be continued 
as pre-pandemic. Similarly, umbilical cord blood banking can be done if the 
 parents desire.
11. Lactation and COVID-19
Several studies have detected SARS-CoV2 nucleic acid in breast milk. However, 
infectious virus particles have not been detected in breast milk [33]. Also, antibod-
ies specific to SARS-CoV2 have also been detected in breast milk, which could 
potentially protect the neonate. Therefore, it is recommended to continue breast-
feeding in mothers with SARS-CoV2 infection, with precautions. These precautions 
include hand hygiene before breast feeding and wearing a face mask. Breast milk 
may be expressed after hand-hygiene and fed to infant by uninfected care-provider 
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12. Pregnancy and COVID-19 vaccines
Clinical trials to determine safety and efficacy of SARS-CoV2 vaccines have 
excluded pregnant women and so data on safety of vaccines in pregnancy is sparse. 
However, the vaccines that are not live attenuated are generally considered safe 
in pregnancy. Also, the animal studies done for safety and efficacy of the current 
vaccines for SARS-CoV2 have not shown any evidence of teratogenicity. RCOG 
recommends that SARS-CoV2 vaccine should be offered to pregnant women at the 
same time as general population [34]. ACOG recommends that mRNA vaccines for 
SARS-CoV2 should not be withheld from pregnant women and should be offered 
to lactating women [35]. It would be prudent to make the decision regarding use of 
SARS-CoV2 vaccines in pregnancy keeping in mind the activity of virus in commu-
nity, risks and potential severity of illness in woman, efficacy of vaccine and risks to 
mother and fetus due to vaccination [35].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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